DNA Topoisomerases in Cancer Therapy: Present and Future PDF
Preview DNA Topoisomerases in Cancer Therapy: Present and Future
DNA Topoisomerases in Cancer Therapy Present and Future DDNNAA TTooppooiissoommeerraasseess iinn CCaanncceerr TThheerraappyy PPrreesseenntt aanndd FFuuttuurree EEddiitteedd bbyy TToosshhiiwwoo AAnnddoohh SSoollccaa UUnniivveerrssiittyy TTookkyyoo,, JJaappaann SSpprriinnggeerr SScciieennccee++BBuussiinneessss MMeeddiiaa,, LLLLCC LLiibbrraarryy ooff CCoonnggrreessss CCaattaallooggiinngg--iinn--PPuubblliiccaattiioonn DDaattaa DDNNAA ttooppooiissoommeerraasseess iinn ccaanncceerr tthheerraappyy :: pprreesseenntt aanndd ffuuttuurree // eeddiitteedd bbyy TToosshhiiwwoo AAnnddoohh.. pp.. ;;ccmm.. IInncclluuddeess bbiibblliiooggrraapphhiiccaall rreeffeerreenncceess aanndd iinnddeexx.. IISSBBNN 997788--11--44661133--44994411--99 IISSBBNN 997788--11--44661155--00114411--11 ((eeBBooookk)) DDOOII 1100..11000077//997788--11--44661155--00114411--11 ll.. DDNNAA ttooppooiissoommeerraasseess----IInnhhiibbiittoorrss--TThheerraappeeuuttiicc uussee.. 22.. CCaanncceerr----CChheemmootthheerraappyy.. 11.. AAnnddoohh,, TToosshhiiwwoo.. [[DDNNLLMM:: ll.. DDNNAA TTooppooiissoommeerraasseess----aannttaaggoonniissttss && iinnhhiibbiittoorrss.. 22.. DDrruugg DDeelliivveerryy SSyysstteemmss.. 33.. NNeeooppllaassmmss----ddrruugg tthheerraappyy.. QQUU 113377 DD662299 22000033]] RRCC2277ll..DD5544DD55333322000033 22000033004444771177 IISSBBNN 997788--11--44661133--44994411--99 ©©22000033 SSpprriinnggeerr SScciieennccee++BBuussiinneessss MMeeddiiaa NNeeww YYoorrkk OOrriiggiinnaa1111yy ppuubblliisshheedd bbyy KKlluuwweerr AAccaaddeemmiiccllPPlleennuumm PPuubblliisshheerrss,, NNeeww YYoorrkk iinn 22000033 SSooffttccoovveerr rreepprriinntt ooff tthhee hhaarrddccoovveerr 11ss tt eeddiittiioonn 22000033 hhttttpp::////wwwwww..wwkkaapp..nnllll 1100 99 88 77 66 55 44 33 22 ll AA CC..II..PP.. rreeccoorrdd ffoorr tthhiiss bbooookk iiss aavvaaiillaabbllee ffrroomm tthhee LLiibbrraarryy ooff CCoonnggrreessss AAIIII rriigghhttss rreesseerrvveedd NNoo ppaarrtt ooff tthhiiss bbooookk mmaayy bbee rreepprroodduucceedd,, ssttoorreedd iinn aa rreettrriieevvaall ssyysstteemm,, oorr ttrraannssmmiitttteedd iinn aannyy ffoorrmm oorr bbyy aannyy mmeeaannss,, eelleeccttrroonniicc,, mmeecchhaanniiccaall,, pphhoottooccooppyyiinngg,, mmiiccrrooffiillmmiinngg,, rreeccoorrddiinngg,, oorr ootthheerrwwiissee,, wwiitthhoouutt wwrriitttteenn ppeerrmmiissssiioonn ffrroomm tthhee PPuubblliisshheerr,, wwiitthh tthhee eexxcceeppttiioonn ooff aannyy mmaatteerriiaall ssuupppplliieedd ssppeecciiffiiccaallllyy ffoorr tthhee ppuurrppoossee ooff bbeeiinngg eenntteerreedd aanndd eexxeeccuutteedd oonn aa ccoommppuutteerr ssyysstteemm,, ffoorr eexxcclluussiivvee uussee bbyy tthhee ppuurrcchhaasseerr ooff tthhee wwoorrkk.. Contributors Toshiwo Andoh Department of Bioengineering Faculty of Engineering Soka University 1-236 Tangi-cho Hachioji, Tokyo 192-8577 Japan Juana Barcel6 Laboratory of Molecular Phannacology Center for Cancer Research National Cancer Institute Bethesda, Maryland 20892-8322 USA Mary-Ann Bjomsti Department of Molecular Phannacology St Jude Children's Research Hospital 332 N. Lauderdale Memphis, Tennessee 38105 USA Kenneth D. Bromberg Department of Biochemistry and Medicine Vanderbilt University School of Medicine Nashville, Tennessee 37232-0146 USA v vi Contributors Takahisa Furuta r Laboratory of Molecular mnacology Center for Cancer Research National Cancer Institute Bethesda Maryland 20892-8322 USA Herve R. Jacquiau Department of Molecular Pharmacology St Jude Children's Research Hospital 332 N. Lauderdale Memphis, Tennessee 38105 USA ZhiYo ng Liao Laboratory of Molecular Pharmacology Center for Cancer Research National Cancer Institute Bethesda Maryland 20892-8322 USA LeroyF. Liu Department of Pharmacology UMDNJ-Robert Wood Johnson Medical School 675 Hoes Lane Piscataway, New Jersey 08854 USA Mobeen Malik Department of Molecular Pharmacology St Jude Children's Research Hospital 332 N. Lauderdale Memphis, Tennessee 38105 USA LingHua Meng Laboratory of Molecular Pharmacology Center for Cancer Research National Cancer Institute Bethesda Maryland 20892-8322 USA Contributors vii John L. Nitiss Department of Molecular Pharmacology St Jude Children's Research Hospital 332 N. Lauderdale Memphis, Tennessee 38105 USA Neil Osheroff Department of Biochemistry and Medicine Vanderbilt University School of Medicine Nashville, Tennessee 37232-0146 USA Yves Pommier Laboratory of Molecular Pharmacology Center for Cancer Research National Cancer Institute Bethesda Maryland 20892-8322 USA Olivier Sordet Laboratory of Molecular Pharmacology Center for Cancer Research National Cancer Institute Bethesda Maryland 20892-8322 USA Haruyuki Takemura Laboratory of Molecular Pharmacology Center for Cancer Research National Cancer Institute Bethesda Maryland 20892-8322 USA KenUmemura Department of Molecular Genetics National Institute of Neuroscience National Center for Neurology and Psychiatry (NCNP) 4-1-1 Ogawahigashi-cho, Kodaira Tokyo 187-8502 Japan viii Contributors James C. Wang Department of Molecular and Cellular Biology Harvard University 7 Divinity Avenue Cambridge Massachusetts 02138 USA Takao Yamori Cancer Chemotherapy Center Japanese Foundation for Cancer Research 1-37-1 Kami-ikebukuro, Toshima-ku Tokyo 170-8455 Japan KaeYanase Department of Bioengineering Faculty of Engineering Soka University 1-236 Tangi-cho Hachioji, Tokyo 192-8577 Japan Preface The year 200 1 was the 30th anniversary of the historical discovery of a novel enzyme DNA topoisomerase I in E. coli, then called "omega" protein, by the pioneering work of Jim Wang, who contributed to this book a memorial article, "Reflections on an Accidental Discovery" of the enzyme. The fascinating story of the discovery of the enzyme described in Chapter 1 should enchant scientists and students as well to show how an important discovery in science is made. As Jim wrote in the "Postscript" of the chapter, this article is a detailed version of what he presented as a memorial lecture at the 2001 meeting on "DNA Topoisomerases in Therapy" symposium series organized by Prof. Milan Potmesil in New York and Prof. Giuseppe Giaccone in Amsterdam since 1986. A rush of discovery of several kinds of topoisomerases, type I through type VI, in a variety of organisms ranging from viruses, bacteria, lower eukaryotes, to higher eukaryotes followed the "omega" protein over decades. The wide distribution of the enzymes in various forms of organisms implicates that DNA topoisomerases are essential for life. It turned out that they are in fact involved in essentially every aspect of genetic processes, such as DNA replication, transcription, recombination, and chromosome dynamics by regulating the topology of DNA. Furthermore, later in the mid 1980' s type I and II enzymes were found to be the intracellular targets of a number of efficacious anticancer therapeutics such as doxorubicin, mitoxantrone, etoposide, and camptothecin, which attracted the interest of scientists and clinicians. In this book the reader finds a series of chapters written by researchers actively involved in the expanding research field. The volume is designed to compile and disseminate up-to-date information on pharmacology and molecular biology of topoisomerase inhibitors now available in cancer clinics and those in stages of clinical and preclinical development. The editor hopes the volume will be useful as a long-standing reference book for clinicians, scientists, and students as well in the field of pharmacology, toxicology, oncology, and molecular biology, and to help further the development of efficacious anticancer therapeutics. The editor wishes to acknowledge the invaluable help of colleagues listed in this volume who provided critical reviews for the book. I offer them all my most sincere thanks, and at the same time apologies for my arbitrary selection of topics in this volume. Thanks are due to Dr. Kae Yanase, one of the contributors to the book, for expert editorial and secretarial assistance. Lastly, I am most grateful to the publishing editor Joanna Lawrence and staff of Kluwer AcademiclPlenum Publishers for patience and generosity. ToshiwoAndoh ix Contents Chapter 1 ...................................................................................................... 1 Reflections on an accidental discovery James C. Wang Chapter 2 .................................................................................................... 15 Mechanisms of topoisomerase I inhibition by anticancer drugs Yves Pommier, Juana BarcelO, Takahisa Furuta, Haruyuki Takemura, and Olivier Sordet Chapter 3 .................................................................................................... 53 Mechanism of action of topoisomerase II-targeted anticancer drugs Kenneth D. Bromberg and Neil Osheroff Chapter 4 .................................................................................................... 79 Degradation of topoisomerase cleavable complexes Leroy F. Liu Chapter 5 .................................................................................................... 89 Yeast as a model system in the analysis of DNA topoisomerase I poisons Herve R. Jacquiau and Mary-Ann Bjornsti Chapter 6 .................................................................................................. 10 9 Understanding the action of drugs targeting TOP2: Yeast based systems for unraveling drug mechanisms Mobeen Malik and John L Nitiss Chapter 7 .................................................................................................. 129 Cellular resistance to DNA topoisomerase I-targeting drugs Kae Yanase and Toshiwo Andoh xi xii Contents Chapter 8 .................................................................................................. 145 Development of new topoisomerase I-targeting compounds as candidate anticancer drugs Yves Pommier, ZhiYong Liao and LingHua Meng Chapter 9 .................................................................................................. 167 Development of new topoisomerase II-targeting compounds as candidate anticancer drugs Toshiwo Andoh, Ken Umemura, Kae Yanase and Takao Yamori Index .......................................................................................................... 189
The list of books you might like
